At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Apr 23, 2026 at 16:07 ET
Vaxcyte, Inc. (PCVX) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 15, 2026. The meeting will vote on the election of three Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation. The filing is routine and does not contain any material financial data or significant corporate actions.
- The filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
- The meeting will be held on June 15, 2026.
- Proposals include the election of three Class III directors: Olivier Brandicourt, Halley Gilbert, and Grant E. Pickering.
- The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 will be ratified.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access